Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Weber Discusses Sequential Versus Concurrent Immunotherapy in Melanoma

August 9th 2016

Jeffery S. Weber, MD, PhD, discusses findings from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

Dr. Fischkoff on Vision for TIL Therapy in Melanoma

August 3rd 2016

Steven A. Fischkoff, MD, chief medical officer of Lion Biotechnologies, Inc, discusses his vision for tumor-infiltrating lymphocyte therapy for patients with melanoma.

Dr. Keith T. Flaherty on 3-Year Follow-up of COMBI-d in Metastatic Melanoma

August 2nd 2016

Dr. Kaufman on Avelumab in Merkel Cell Carcinoma

July 28th 2016

Howard L. Kaufman, MD, chief surgical officer, associate director for clinical science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses the phase II JAVELIN Merkel 200 study examining avelumab as a treatment for patients with Merkel cell carcinoma.

Long-Term Follow-up Sustains Sonidegib Benefit in Basal Cell Carcinoma

July 20th 2016

The hedgehog inhibitor sonidegib (Odomzo) showed continued antitumor activity with no new safety concerns in patients with advanced basal cell carcinoma.

Large Trial Confirms Vismodegib Benefit in Basal Cell Carcinoma

July 19th 2016

The hedgehog inhibitor vismodegib (Erivedge) had an estimated disease control rate of 92.9% in the STEVIE trial, the largest ever study conducted in advanced basal cell carcinoma.

Multi-Modality Treatment in Basal Cell Carcinoma

July 14th 2016

Novel Approaches in Melanoma

July 14th 2016

Managing Lesions in Melanoma

July 14th 2016

Combination Strategies in Melanoma

July 14th 2016

Melanoma: Considerations in Checkpoint Inhibition

July 14th 2016

Managing Brain Metastases and Side Effects in Melanoma

July 14th 2016

Melanoma: BRAF/MEK Targeted Therapy

July 14th 2016

Need for Subgroup Analyses in Melanoma Trials

July 14th 2016

Disease Burden and First-Line Melanoma Treatment

July 14th 2016

Neoadjuvant Strategies in Melanoma

July 14th 2016

Immunotherapy in Advanced Melanoma

July 14th 2016

Initial Strategies in Advanced Melanoma

July 14th 2016

Validity of PD-L1 Testing in Melanoma

July 14th 2016

Mutations of Clinical Significance in Melanoma

July 14th 2016